Jasper T W, Ruh M F, Ruh T S
J Steroid Biochem. 1985 Nov;23(5A):537-45. doi: 10.1016/0022-4731(85)90001-9.
Our laboratory has previously reported that calf uterine cytosol prepared in buffer containing 10 mM molybdate and chromatographed on DEAE-Sephadex contains two forms of the unactivated estrogen receptor, Peak I and Peak II; however, cytosol receptor bound to the high-affinity antiestrogen, H1285 (4-(N,N-diethylaminoethoxy)-4'-methoxy-alpha- (p-hydroxyphenyl)-alpha'-ethylstilbene), eluted only as Peak I. We have extended these studies to the rat uterus and pituitary in order to determine the organ and species specificity of this phenomenon. Cytosol prepared in Tris-molybdate buffer from immature and adult rat uteri or pituitaries was labelled with 10 nM [3H]estradiol or [3H]H1285 and chromatographed on QAE-Sephadex. Uterine estrogen receptors bound to either [3H]estradiol or [3H]H1285 eluted from QAE-Sephadex as a large Peak I (approximately 0.21 M KCl) and a smaller Peak II (approximately 0.25 M KCl). Analyses of these partially purified estrogen receptor fractions using high-salt sucrose density gradients showed that Peak I [3H]estradiol-receptor complexes sedimented predominantly as a lighter form (4.0S). In contrast, Peak I [3H]H1285-receptor complexes sedimented primarily as a heavier form (5.5S) often accompanied by a smaller lighter form (4.0S). Peak II [3H]estradiol- and [3H]H1285-receptor complexes sedimented as the heavier form (5.3-5.5S). These data suggest a monomer-dimer relationship between estrogen receptor forms with antiestrogen binding favoring the formation of the dimeric form. Further analysis of these Peak I receptor complexes by gel filtration chromatography yielded molecular forms of approx 70 KDaltons for [3H]estradiol-receptor complexes and 73 KDaltons and 165 KDaltons for [3H]H1285-receptor complexes, supporting the monomer-dimer concept. Data from experiments with the pituitary also suggest that H1285 causes the formation of the dimeric receptor form whereas estradiol interaction with the receptor results only in the monomeric form. These differences in estrogen receptor forms when bound by estrogen versus antiestrogen may be related to the different biological responses induced by these ligands.
我们实验室之前报道过,在含有10 mM钼酸盐的缓冲液中制备并经DEAE - 葡聚糖凝胶层析的小牛子宫胞质溶胶含有两种未活化的雌激素受体形式,峰I和峰II;然而,与高亲和力抗雌激素H1285(4 - (N,N - 二乙氨基乙氧基) - 4'-甲氧基 - α - (对羟基苯基) - α'-乙基己烯雌酚)结合的胞质溶胶受体仅以峰I形式洗脱。我们将这些研究扩展到大鼠子宫和垂体,以确定这种现象的器官和物种特异性。用10 nM [3H]雌二醇或[3H]H1285标记从未成熟和成年大鼠子宫或垂体中在Tris - 钼酸盐缓冲液中制备的胞质溶胶,并在QAE - 葡聚糖凝胶上进行层析。与[3H]雌二醇或[3H]H1285结合的子宫雌激素受体从QAE - 葡聚糖凝胶上洗脱时呈现出一个大的峰I(约0.21 M KCl)和一个较小的峰II(约0.25 M KCl)。使用高盐蔗糖密度梯度对这些部分纯化的雌激素受体组分进行分析表明,峰I [3H]雌二醇 - 受体复合物主要以较轻的形式(4.0S)沉降。相比之下,峰I [3H]H1285 - 受体复合物主要以较重的形式(5.5S)沉降,通常伴有一个较小的较轻形式(4.0S)。峰II [3H]雌二醇 - 和[3H]H1285 - 受体复合物以较重的形式(5.3 - 5.5S)沉降。这些数据表明雌激素受体形式之间存在单体 - 二聚体关系,抗雌激素结合有利于二聚体形式的形成。通过凝胶过滤层析对这些峰I受体复合物进行进一步分析,得到[3H]雌二醇 - 受体复合物的分子形式约为70千道尔顿,[3H]H1285 - 受体复合物的分子形式为73千道尔顿和165千道尔顿,支持了单体 - 二聚体概念。垂体实验的数据也表明,H1285导致二聚体受体形式的形成,而雌二醇与受体的相互作用仅产生单体形式。当与雌激素和抗雌激素结合时,雌激素受体形式的这些差异可能与这些配体诱导的不同生物学反应有关。